![](images/graphics/blank.gif)
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
Chia sẻ: ViOrochimaru2711 ViOrochimaru2711 | Ngày: | Loại File: PDF | Số trang:8
![](images/blank.gif)
8
lượt xem 1
download
lượt xem 1
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD